Recombinant NKG2A (Monalizumab Biosimilar) antibody
This Humanized Monoclonal antibody specifically detects NKG2A (Monalizumab Biosimilar) in ELISA and WB. It exhibits reactivity toward Human.
Catalog No. ABIN7538069
$336.06
Plus shipping costs $50.00
Shipping to:
United States
Delivery in 7 to 10 Business Days
Quick Overview for Recombinant NKG2A (Monalizumab Biosimilar) antibody (ABIN7538069)
Target
NKG2A (Monalizumab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
Humanized
Clonality
Monoclonal
Conjugate
This NKG2A (Monalizumab Biosimilar) antibody is un-conjugated
Application
ELISA, Western Blotting (WB)
Grade
Research Grade
-
-
Expression System
- Mammalian cells
-
Purpose
- Monalizumab Biosimilar - Anti-KLRC1, NKG2A, CD159a, CD94 mAb - Research Grade
-
Characteristics
- Antibody Type: IgG4-kappa
-
Purification
- Recombinant antibody expressed in mammalien cells and purified.
-
Purity
- > 85%
-
Isotype
- IgG4
-
-
-
-
Restrictions
- For Research Use only
-
-
-
Buffer
- PBS buffer PH7.5
-
Storage
- -80 °C
-
Storage Comment
- store at -80°C
-
-
- NKG2A (Monalizumab Biosimilar)
-
Background
- Monalizumab is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).
-
CAS-No
- 1228763-95-8
Target
-
You are here:
